LMR Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

LMR Partners’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-31,604	Closed	-$2.25M	–	1339
2022 Q1	$2.25M	Buy	+31,604	New	+$2.06M	0.03%	532

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

LMR Partners's ENTA Position: Q2 2022 in Review

LMR Partners sold out of Enanta Pharmaceuticals (ENTA) in Q2 2022, closing a stake of 31,604 shares — an estimated $2.25M sold.

LMR Partners first reported a position in ENTA in Q1 2022 and held it in 1 quarter. The position peaked at $2.25M in Q1 2022. 154 funds tracked by Wall St. Rank hold ENTA as of Q2 2022.

LMR Partners reported no remaining Enanta Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
LMR Partners sold 31,604 Enanta Pharmaceuticals shares in Q2 2022, an estimated $2.25M.
LMR Partners first reported a position in Enanta Pharmaceuticals in Q1 2022 and held it in 1 quarter.
LMR Partners's Enanta Pharmaceuticals position peaked at $2.25M in Q1 2022.
154 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2022.

Based on LMR Partners's 13F filing for Q2 2022, filed 15 Aug 2022.